Skip to content

Emergent Biosolutions EBS Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

CorMedix logo
CorMedixCRMD
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Opko Health logo
Opko HealthOPK
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Medline, Inc.
 logo
Medline, Inc. MDLN
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's accrued liabilities, current?
Emergent Biosolutions (EBS) reported accrued liabilities, current of $9.4M in Q1 2026.
How has Emergent Biosolutions's accrued liabilities, current changed year-over-year?
Emergent Biosolutions's accrued liabilities, current decreased by 28.8% year-over-year, from $13.2M to $9.4M.
What is the long-term trend for Emergent Biosolutions's accrued liabilities, current?
Over 5 years (2020 to 2025), Emergent Biosolutions's accrued liabilities, current has grown at a -23.6% compound annual growth rate (CAGR), from $46.9M to $12.2M.